Search research articles
Contact Us
Filters
Showing results (81-90 of 122) with videos related to
Page
of 13
Sort By:
ESMO Open
|
June 12, 2026
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus
J B Aragon-Ching, S Gupta, P Grivas, et al.
Tumori
|
November 1, 1996
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)
A Ribas, J Bellmunt, J Albanell, et al.
Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|
October 31, 2002
Protein oxidative stress in dialysis patients
Teresa Doñate, Alba Herreros, Ester Martinez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 1998
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
J M Buesa, A López-Pousa, J Martín, et al.
British Journal of Cancer
|
December 24, 2014
Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients
A Orsola, L Werner, I de Torres, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
J Bellmunt, S A Mullane, L Werner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
J Bellmunt, J L González-Larriba, C Prior, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
American Journal of Clinical Oncology
|
August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder
J Bellmunt, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2007
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
J Bellmunt, L Paz-Ares, M Cuello, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 122) with videos related to
Sort By:
Page
of 13
ESMO Open
|
June 12, 2026
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus
J B Aragon-Ching, S Gupta, P Grivas, et al.
Tumori
|
November 1, 1996
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)
A Ribas, J Bellmunt, J Albanell, et al.
Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis
|
October 31, 2002
Protein oxidative stress in dialysis patients
Teresa Doñate, Alba Herreros, Ester Martinez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 28, 1998
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
J M Buesa, A López-Pousa, J Martín, et al.
British Journal of Cancer
|
December 24, 2014
Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients
A Orsola, L Werner, I de Torres, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
J Bellmunt, S A Mullane, L Werner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
J Bellmunt, J L González-Larriba, C Prior, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
American Journal of Clinical Oncology
|
August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder
J Bellmunt, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2007
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
J Bellmunt, L Paz-Ares, M Cuello, et al.
Page
of 13